This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Optimizing the Treatment of IBD: Expanding Possibilities with Treat-to-Target Strategies

Optimizing the Treatment of IBD: Expanding Possibilities with Treat-to-Target Strategies

Format

Roundtable

Time to Complete

1 hour

Released

December 14, 2018

Expires

December 14, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE Contact Hour (1.00 of which is eligible for pharmacology credit)

Accredited Provider



Provided by Boston University School of Medicine

Commercial Supporter

This activity is supported by an independent educational grant from Abbvie Inc., Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Takeda Pharmaceuticals USA Inc., and Pfizer Inc.

Program Description

Advances in treatments and the presence of biologic therapies have reshaped the goals of inflammatory bowel disease (IBD) treatment and give patients a better chance of achieving remission. However, many patients continue to live with symptoms of moderate-to-severe disease and those that do achieve symptomatic relief may continue to have inflammatory activity that leads to progressive damage. Goals now need to reach beyond symptom control to benefit patients in the long-term.

Though a growing body of evidence supports early aggressive treatment to decrease mucosal inflammation and slow disease progression in patients with IBD, many gastroenterologists rely on outdated approaches and less effective traditional therapies.

Utilizing an expert multidisciplinary faculty panel and featuring video vignettes of ideal patient education encounters, this activity reviews the growing evidence to support IBD treat-to-target strategies, the targets physicians can aim for to achieve tight control in their patients and also the most current treatment options when therapeutic targets are not met, especially for patients who have failed to achieve remission.

Intended Audience

Gastroenterologists, gastroenterology fellows, primary care physicians, NPs, PAs, nurses, pharmacists and others who manage/treat patients with IBD

Educational Objectives

Upon completion of these activities, participants should be better able to:

  • Discuss the safety and efficacy of novel treatments with unique therapeutic targets for IBD.
  • Integrate treat-to-target strategies in practice for patients with IBD to improve outcomes and slow disease progression.
  • Design personalized treatment plans for patients with IBD who fail to achieve remission.
  • Building an effective care team to manage patients with IBD

Conflict Of Interest Disclosure Policy

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty

Francis A. Farraye, MD, MSc
Course Director
Clinical Director in the Section of Gastroenterology
Director of the Inflammatory Bowel Disease Center
Boston Medical Center
Professor of Medicine
Boston University School of Medicine
Boston, Massachusetts

Dr. Farraye is a consultant for Braintree Laboratories, Janssen Biotech, Inc., Merck & Co. Inc., Pfizer Inc., and Takeda Pharmaceuticals, USA, Inc. He also is a stockholder and on the advisory board for Innovation Pharmaceuticals and is on the data safety management board for Eli Lilly and Company and Theravance Biopharma.

Alan C. Moss, MD, FACG, FEBG, AGAF, FRCPI
Director of Translational Research
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School

Dr. Moss is a consultant for Janssen Biotech Inc., Theravance Biopharma, and Seres Therapeutics, Inc.

Beth-Ann Norton, MS, RN, ANP-BC
Nurse Practitioner and Nursing Program Director
Brigham and Women’s Hospital Crohn's and Colitis Center
Chestnut Hill, MA

Ms. Beth-Ann Norton is a consultant for Takeda Pharmaceuticals, USA, Inc.

Accredited Provider Disclosure

Michael Burk, Senior Program Manager for Boston University School of Medicine’s Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Carmela Townsend, Lead Nurse Planner, Boston University School of Medicine's Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Dana Frazier, Program and Grant Manager for Boston University School of Medicine’s Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Bret Lashner, MD, planning committee member for Boston University School of Medicine’s Office of Continuing Medical Education and Professor of Medicine at the Cleveland Clinic, has no relevant financial relationships to disclose.

Laura Stinson, consultant medical editor for Boston University School of Medicine’s Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

Boston University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CNE Contact Hour(s)

Accreditation Statement

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Designation Statement

CNE Contact Hours: 1.00, all of which is eligible for pharmacology credit.

Disclosure of Unlabeled Use

The faculty members do discuss unlabeled/investigational uses of a commercial product.

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

Instructions

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.00 AMA PRA Category 1 Credit and nurses are entitled to receive 1.00 CNE contact hour. Statements of credit will be available to print immediately. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians and nurses who successfully complete the post-test and evaluation will receive CME or CNE credit respectively. You must score with a 70% or higher on the post-test to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

For any CME or CNE accreditation questions please email the BUSM CME office at cme@bu.edu.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue